- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Sera Prognostics names Scott Gleason as chief financial officer | 2 | Investing.com | ||
| 19.08. | Sera Prognostics appoints Scott Gleason as CFO, effective Aug. 31 | 1 | Seeking Alpha | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.08. | Sera Prognostics ernennt Scott Gleason zum neuen Finanzvorstand | 1 | Investing.com Deutsch | ||
| 19.08. | Sera Prognostics, Inc.: Sera Prognostics Appoints Scott Gleason Chief Financial Officer | 419 | PR Newswire | SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 12.08. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2026 Financial Results | 201 | PR Newswire | SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 09.07. | Sera Prognostics study shows NICU admission cut in first births | 1 | Investing.com | ||
| 30.06. | Sera Prognostics adds former Myriad Genetics CEO to board | 1 | Investing.com | ||
| 30.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.06. | All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy | 1 | Zacks | ||
| 01.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial Results | 856 | PR Newswire | SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing... ► Artikel lesen | |
| 06.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial Results | 524 | PR Newswire | SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 1.068 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 01.10.25 | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 305 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,832 | -0,07 % | RALLYE bei Valneva: +37,7% Potenzial - Jetzt einsteigen? | ||
| NANOREPRO | 1,680 | -1,75 % | NanoRepro-Aktie: Ist das der beste Nano Cap? | Die NanoRepro AG möchte eine breit aufgestellte Consumer-Health-Plattform entwickeln. Die Aktie ist nach ihren Höhenflug zur Jahresmitte wieder deutlich zurückgekommen. Wie geht es jetzt weiter? Ambitionierte... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,630 | -2,48 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,902 | -2,80 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| COSCIENS BIOPHARMA | 4,425 | +1,96 % | Cosciens Biopharma Inc (2): Cosciens closes second tranche of debenture offering | ||
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| VIVORYON THERAPEUTICS | 1,095 | +0,46 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,582 | +1,23 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,540 | 0,00 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,209 | +1,77 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| REDHILL BIOPHARMA | 0,558 | -1,78 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,120 Euro und damit +0,47 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.